

INDEX

Note: Page numbers of article titles are in **boldface** type.

- Adenocarcinoma, cervical,
 immunohistochemical techniques in,
 731-732
 microinvasive, 498-500
 endometrial, endometrioid, 519-523
 immunohistochemical techniques in,
 732-733
 villoglandular, 520-521
 ovarian, 734-736
- Adenofibroma, uterine, 546-548
- Adenoid basal carcinoma, cervical,
 503-504
- Adenoid cystic carcinoma, cervical,
 504-505
- Adenoid squamous cell carcinoma, vulvar,
 476
- Adenomatoid tumor, ovarian, 604-605
- Adenomyoma, uterine, 536-537, 548-549
- Adenosarcoma, uterine, 532-536, 549-551
- AE antibodies, in gynecologic disease
 diagnosis, 728-729
- Aggressive angiomyxoma, vulvar, 482-484
- Alkaline phosphatase, placental, in
 gynecologic tumors, 735, 737
- Alpha-fetoprotein, in ovarian tumor
 diagnosis, 734
- Angiomyofibroblastoma, vulvar, 464
- Angiomyxoma, aggressive, vulvar, 482-484
- Antibodies, in disease diagnosis. See
 Immunohistochemical techniques.
- Arias-Stella reaction, 506, 508, 527
- Aspiration cytology, fine-needle, of ovary.
 See under *Ovary.*
- Atypical polypoid adenomyoma, uterine,
 536-537, 548-549
- Atypical squamous epithelium of
 undetermined significance, cervical,
 694, 696-697
- Bartholin's gland, carcinoma of, 481
- Basal cell carcinoma, vulvar, 478-479
- Basiloid squamous cell carcinoma, vulvar,
 475
- Bethesda system, in Pap smear
 classification, 693-694
- Bowenoid papulosis, vulvar, 461-462
- Brenner tumors, 718, 736-737
- CA-125 antigen, in gynecologic tumors,
 735-736, 744-745, 748
- CAM antibodies, in gynecologic disease
 diagnosis, 728-729
- Carcinoembryonic antigen, antibodies to,
 in gynecologic disease diagnosis, 730
- Carcinoid tumors, ovarian, 601-602, 719,
 721
- Carcinoma. See also *Adenocarcinoma.*
 adenoid basal, cervical, 503-504
 adenoid cystic, cervical, 504-505
 Bartholin's gland, 481
 basal cell, vulvar, 478-479
 cervical. See under *Cervical lesions.*
 ciliated, endometrial, 520, 522
 clear cell, endometrial, 523, 525, 527
 ovarian, 718
 embryonal, 721, 723
 endometrial. See under *Endometrial tu-
 mors.*
 endometrioid, ovarian, 588-589, 717-718
 glassy cell, cervical, 500-502
 lymphoepithelioma-like, cervical, 501-
 503
 metastatic, ovarian, 724
 mucinous, endometrial, 525-526
 ovarian. See *Ovarian neoplasms, carci-
 noma.*
 papillary, endometrial, 527-528
 secretory, endometrial, 520
 serous, endometrial, 523-524
 small cell, immunohistochemical tech-
 niques in, 738
 ovarian, 605-607

- Carcinoma (*Continued*)
- squamous cell. See *Squamous cell carcinoma*.
 - transitional cell, ovarian, 589-591
 - undifferentiated, endometrial, 526
 - verrucous, vulvar, 475-476, 729
 - vulvar. See under *Vulvar lesions*.
- Carcinosarcoma, uterine, 529-532, 551-554
- Cell culture, in chlamydial infections, 667-668
- in herpes simplex virus infections, 677-678
- Cellular leiomyoma, uterine, 568
- Cervical lesions, 493-516
- adenocarcinoma, 498-500, 731-732
 - Arias-Stella reaction, 506, 508
 - atypical squamous epithelium of undetermined significance, 694, 696-697
 - carcinoma, adenoid basal, 503-504
 - adenoid cystic, 504-505
 - advanced, treatment of, 761-763
 - early stage, treatment of, 757-761
 - glassy cell, 500-502
 - human papillomavirus and, invasive, 700
 - morphologic changes in, 694-698
 - pathogenetic mechanisms in, 687-689, 692-693
 - immunohistochemical techniques in, 729-730
 - lymphoepithelioma-like, 501-503
 - squamous cell, microinvasive, 493-497
 - treatment of, 757-763
 - classification of, Bethesda system in, 693-694
 - cystic endocervical tunnel clusters, 509-511
 - histology of, 494-497
 - immunohistochemical techniques in, 729-732
 - intraepithelial neoplasia, human papillomavirus and, epidemiology of, 692-693
 - high-grade squamous, 696-699
 - low-grade squamous, 695-696, 698-699
 - immunohistochemical techniques in, 729-730
 - invasion of, immunohistochemical techniques in, 730-731
 - large loop excision of transformation zone in, 511-512
 - mesonephric remnant hyperplasia, 505-506
 - placental site nodule, 508-509
 - precancerous, human papillomavirus in, 694-695
 - sexually transmitted. See *Sexually transmitted diseases*.
- Chemotherapy, for cervical cancer, 760-761, 763
- for gestational trophoblastic disease, 756-757
 - for ovarian cancer, advanced, 745-749
 - borderline, 750-752
 - germ cell, 753
- Chlamydial infections, diagnosis of, 665-671
- Chorangiocarcinoma, 656, 658
- Chorangioma, 624-626
- Choriocarcinoma, 658, 660-662
- Ciliated carcinoma, endometrial, 520, 522
- CIN. See *Cervical lesions, intraepithelial neoplasia*.
- Clear cell carcinoma, endometrial, 523, 525, 527
- ovarian, 718
- Clear-cell hidradenoma, vulvar, 463
- Coagulopathy, placental vascular lesions in, 616-617
- Condyloma acuminata, human papillomavirus and. See *Human papillomavirus*.
- Corpus luteum, fine-needle aspiration cytology of, 712
- Cyst(s), ovarian, fine-needle aspiration cytology of, 710, 712-713
- Cystic endocervical tunnel clusters, 509-511
- Cystic struma ovarii, 603-604
- Cytology, fine-needle aspiration, of ovary. See *Ovary, fine-needle aspiration cytology of*.
- Cytotrophoblast, pathology of, in gestational trophoblastic disease, 633-634
- Decidual cells, vs. trophoblasts, 738
- Diabetes mellitus, placental vascular lesions in, 617
- Direct fluorescent antibody tests, in chlamydial infections, 668-669
- DNA, in gestational trophoblastic disease, 631-633, 642-644
- Dysgerminoma, ovarian, 721
- E6/E7 oncoproteins, of human papillomavirus, interactions with tumor suppressor gene products, 688-689
- Embryonal carcinoma, ovarian, 721, 723
- Endocervical glands, cystic tunnel clusters of, 509-511
- Endometrial glands, elements of, in uterine neoplasms, 560
- Endometrial tumors, 517-543
- adenocarcinoma, 519-523

- immunohistochemical techniques in, 732-733
- villoglandular, 520-521
- adenosarcoma, 532-536
- Arias-Stella reaction, 527
- atypical polypoid adenomyoma, 536-537
- carcinoma, ciliated, 520
- classification of, 517
- clear cell, 523, 525, 527
- differential diagnosis of, 527-528
- grading of, 528-529
- hyperplasia with, 517-518
- immunohistochemical techniques in, 732
- mucinous, 525-526
- papillary, 527-528
- secretory, 520
- serous, 523-524
- squamous cell, 526
- staging of, 528-529
- undifferentiated, 526
- carcinosarcoma, 529-532, 551-554
- hormone receptors in, 560-562
- metaplastic, 537-540
- sex cord elements in, 559-560
- stromal, 555-562, 732
- treatment of, 754-756
- Endometrioid tumors, endometrial, adenocarcinoma, 519-523
- ovarian, 717-718
- carcinoma, 588-589, 717-718
- intermediate, 586-588
- Endometriosis, fine-needle aspiration cytology of, 713
- Endometrium, hyperplasia of, carcinoma with, 517-518
- in gestational trophoblastic disease, 634, 637
- tumors of. See *Endometrial tumors*.
- Endovascularitis, hemorrhagic, placental, 622-624
- Enzyme immunoassays, in chlamydial infections, 669
- Epithelial components, in uterine mesenchymal tumors, 545-554, 733
- Estrogen receptors, in endometrial stromal tumors, 560-562
- Fetus, placental circulation of, vascular disorders of, 620-626
- twin, in molar pregnancy, 638-640
- Fine-needle aspiration cytology, of ovary. See under *Ovary*.
- Flow cytometry, in gestational trophoblastic disease, 642
- Follicular cysts, fine-needle aspiration cytology of, 710, 712
- Genital warts, human papillomavirus and. See *Human papillomavirus*.
- Germ cell tumors, ovarian, 599-604, 737
- fine-needle aspiration cytology of, 719-723
- treatment of, 753
- Gestational trophoblastic disease, 631-664
- choriocarcinoma, 658, 660-662
- classification of, 632
- hydatidiform mole, complete, 632-644
- diagnosis of, 633, 642-644
- early, 637-638
- invasive, 641
- natural history of, 640-641
- pathology of, 633-638
- with normal twin, 638-640
- immunohistochemical techniques in, 738
- partial, 644-649
- hydropic abortus, 649-650
- immunohistochemical techniques in, 738
- placental site lesions, chorangiocarcinoma, 656, 658-659
- nodules, 508-509, 650-654
- trophoblastic tumor, 655-657
- treatment of, 756-757
- Glassy cell carcinoma, cervical, 500-502
- Glial fibrillary acidic protein, antibodies to, in gynecologic disease diagnosis, 732
- Gonadotropin hormone-releasing hormone agonists, uterine leiomyoma and, 567-568
- Gonorrhea, diagnosis of, 672-675
- Granular cell tumors, vulvar, 464
- Granulosa cell tumors, ovarian, 718
- Gynecologic pathology, cervical lesions. See *Cervical lesions*.
- endometrial tumors. See *Endometrial tumors*.
- gestational trophoblastic disease, 631-664
- human papillomavirus infections, 685-704
- immunohistochemical approaches in, 727-742
- oncologic disease, 743-770
- ovarian neoplasms. See *Ovarian neoplasms*.
- placental vascular lesions, 611-629
- sexually transmitted diseases, 665-684
- uterine neoplasms. See *Uterine neoplasms*.
- vulvar lesions. See *Vulvar lesions*.
- Hemorrhagic endovascularitis, placental, 622-624
- Herpes simplex virus infections, diagnosis of, 675-678
- Hidradenoma, vulvar, 462-463

- Hormone receptors, in endometrial stromal tumors, 560-562
- Human papillomavirus, **685-704**
 classification of, 686
 detection of, 691-692
 genetics of, 686-687
 in cervical cancer, invasive, 700
 morphologic changes in, 694-698
 pathogenetic mechanisms in, 687-689, 692-693
 in vulvar intraepithelial neoplasia, 700-701
 infections with, diagnosis of, 680
 epidemiology of, 692-693
 high-grade squamous intraepithelial lesion in, 696-699
 histological difficulties in, 698
 low-grade squamous intraepithelial lesion in, 695-696, 698-699
 morphology of, 694-698
 occult, 699-700
 pregnancy and, 699
 life cycle of, 689-691
- Hydatidiform mole. See under *Gestational trophoblastic disease*.
- Hydropic abortus, 649-650
- Hypercalcemia, in ovarian small cell carcinoma, 605-606
- Hypertension, essential, placental vascular lesions in, 617
- Immunohistochemical techniques, in gynecologic pathology, **727-742**
 cervical, 729-732
 endometrial, 732-734
 ovarian, 734-738
 placental, 738
 uterine, 734
 vulvar, 727-729
- In situ hybridization, in human papillomavirus detection, 691-692
- Interphase cytogenetic analysis, in gestational trophoblastic disease, 643
- Intervillous space, vascular lesions of, 617-620
- Intestinal type, of ovarian mucinous tumor, 582-584
- Intraepithelial neoplasia, cervical, human papillomavirus and,
 epidemiology of, 692-693
 high-grade squamous, 696-699
 low-grade squamous, 695-696, 698-699
 immunohistochemical techniques in, 729-730
 vulvar, 457-461, 700-701, 728-729
- Intravenous leiomyomatosis, of uterus, 565-567
- Keratin, antibodies to, in gynecologic disease diagnosis, 728-732, 734
- Keratinized squamous cell carcinoma, vulvar, 475
- Keratoacanthoma, vulvar, 462
- Koilocytes, human papillomavirus and, 685
- Krukenberg tumor, ovarian, 607-608
- Laparoscopy, ovarian aspiration cytology in, 707
- Large loop excision of transformation zone, in cervical lesions, 511-512
- Leiomyoma, uterine, atypical, 569-571
 cellular, 568
 gonadotropin hormone-releasing hormone agonists and, 567-568
 mitotically active, 568-569
- Leiomyomatosis, intravenous, of uterus, 565-567
- Leiomyosarcoma, uterine, 562-565
- Leydig cell tumors, ovarian, 597-599
- Lichen sclerosis, vulvar, 457
- LLETZ (large loop excision of transformation zone), in cervical lesions, 511-512
- Luteal cysts, fine-needle aspiration cytology of, 712
- Lymphoepithelioma-like carcinoma, cervical, 501-503
- Lymphoma, ovarian, 723
- Malignant melanoma, vulvar, 481-482, 727-728, 764-765
- Malignant mixed müllerian tumor (carcinosarcoma), uterine, 529-532, 551-554
- Maternal floor infarct, of placenta, 619-620
- Melanoma, malignant, vulvar, 481-482, 727-728, 764-765
- Mesenchymal tumors, uterine. See under *Uterine neoplasms*.
- Mesonephric remnant hyperplasia, cervical, 505-506
- Mesothelial tumors, ovarian, 604-605
- Metaplasia, endometrial, 537-540
- Metastasis, to ovary, 607-608, 724
- Microinvasive cervical neoplasms, adenocarcinoma, 498-500
 squamous cell carcinoma, 493-497
- Mitotically active leiomyoma, uterine, 568-569
- Molar pregnancy. See *Gestational trophoblastic disease*.
- Monodermal teratoma, ovarian, 600-604
- Mucinous tumors, endometrial carcinoma, 525-526

- ovarian, carcinoid, 601-602
 fine-needle aspiration cytology of, 715-717
 low malignant potential, 582-584
 metastatic, 607-608
 pseudomyxoma peritonei in, 585-586
- Müllerian tumors, ovarian, 582-584
- Myometrial neoplasms. See *Uterine neoplasms, mesenchymal*.
- Needle aspiration, of ovary. See *Ovary, fine-needle aspiration cytology of*.
- Neisseria gonorrhoeae* infections, diagnosis of, 672-675
- Neuroectodermal tumors, primitive, ovarian, 600-601
- Nodules, placental site, 508-509, 650-654
- Non-neoplastic epithelial disorders, vulvar, 455-457
- Nucleic acid hybridization tests, in chlamydial infections, 670
- Oncogenes, in cervical cancer, human papillomavirus and, 686-689
- Ovarian neoplasms, 595-610
 adenocarcinoma, 734-736
 adenomatoid tumors, 604-605
 advanced, treatment of, 745-750
 borderline, treatment of, 750-753
 Brenner tumors, 718, 736-737
 carcinoid tumor, 719, 721
 carcinoma, clear cell, 718
 early invasive, treatment of, 750-753
 embryonal, 721, 723
 endometrioid, 588-589
 metastatic, 724
 small cell, 605-607
 transitional cell, 589-591
 clear cell tumors, 718
 dysgerminoma, 721
 embryonal carcinoma, 721, 723
 endometrioid tumors, 586-588, 717-718
 epithelial, 575-593
 advanced, treatment of, 745-750
 borderline, treatment of, 750-753
 screening for, 744-745
 fine-needle aspiration cytology of. See *Ovary, fine-needle aspiration cytology of*.
 germ cell tumors, 599-604, 737
 fine-needle aspiration cytology of, 719-723
 treatment of, 753
 granulosa cell tumors, 718
 immunohistochemical techniques in, 734-737
 intestinal type of mucinous tumor, 582-584
 Krukenberg tumors, 607-608
 lymphoma, 723
 mesothelial tumors, 604-605
 metastatic, 607-608, 724
 monodermal teratoma, 600-604
 mucinous tumors, 607-608
 carcinoid, 601-602
 fine-needle aspiration cytology of, 715-717
 low malignant potential, 582-584
 pseudomyxoma peritonei in, 585-586
 müllerian tumors, 582-584
 primitive neuroectodermal tumors, 600-601
 sclerosing stromal tumors, 595-597
 screening for, 744-745
 sebaceous tumors, 602-603
 serous tumors, fine-needle aspiration cytology of, 714-715
 low malignant potential, 575-581
 implants from, 575-579
 microinvasion of, 579-580
 primary peritoneal, 580-581
 psammocarcinoma, 581-584
 Sertoli-Leydig cell tumors, 597-599, 718-719
 sex cord-stromal tumors, 595-599, 718-719, 736-737
 struma ovarii, 603-604
 teratoma, 719
 yolk sac tumors, 599-600, 721
- Ovary, fine-needle aspiration cytology of, 705-726
 diagnostic accuracy of, 724
 "en route" structure contamination in, 708-710
 functional cysts, 710, 712-713
 indications for, 706
 interpretation of, 707-708
 neoplasms, 713-724
 technique for, 706-707
 neoplasms of. See *Ovarian neoplasms*.
- p53 tumor suppressor gene product, human papillomavirus gene interaction with, 688-689
- Paget's disease, vulvar, 479-481, 727-728
- Pap smear, Bethesda classification of, 693-694
- Papillary carcinoma, endometrial, 527-528
- Papillary hidradenoma, vulvar, 462-463
- Papillary syncytial metaplasia, endometrial, 540
- Peritoneum, implants in, from ovarian serous tumors, 575-579
 mucin pools in (pseudomyxoma peritonei), 585-586

- Peritoneum (*Continued*)
 primary serous tumors of, low malignant potential, 580-581
 serous psammocarcinoma of, 581-584
- Placenta, vascular lesions of, 611-629
 chorangiomas, 624-626
 examination guidelines for, 612-613
 fetal stem artery thrombosis, 620-622
 hemorrhagic endovasculitis, 622-624
 intervillous space, 617-620
 spiral artery, 613-617
 vs. normal circulation, 611-612
- Placental alkaline phosphatase, in gynecologic tumors, 735, 737
- Placental site lesions, chorangiocarcinoma, 656, 658-659
 nodules, 508-509, 650-654
 trophoblastic tumors, 655-657, 738
- Polymerase chain reaction, in chlamydial infections, 670
 in gestational trophoblastic disease, 642, 661-662
 in human papillomavirus detection, 691-692
- Polypoid adenomyoma, atypical, uterine, 536-537, 548-549
- Pre-eclampsia, placental vascular lesions in, 613-616
- Pregnancy, human papillomavirus infections in, 699
 placental vascular lesions in, 611-629
 trophoblastic disease in, 631-664
- Primitive neuroectodermal tumors, ovarian, 600-601
- Progesterone receptors, in endometrial stromal tumors, 560-562
- Psammocarcinoma, serous, ovarian, 581-584
- Pseudomyxoma peritonei, 585-586
- Pulmonic type, of ovarian small cell carcinoma, 606-607
- Radiation therapy, for cervical cancer, 759-760
 for endometrial cancer, 755-756
- Retinoblastoma tumor suppressor gene product, human papillomavirus gene interaction with, 688-689
- S-100 protein, in ovarian tumors, 734
- Sarcoma, stromal, uterine, 555-562, 732
- Sclerosing stromal tumor, ovarian, 595-597
- Sebaceous tumors, ovarian, 602-603
- Secretory carcinoma, endometrial, 520
- Serous tumors, endometrial carcinoma, 523-524
- ovarian. See under *Ovarian neoplasms*.
 psammocarcinoma, 581-584
- Sertoli-form variant, of ovarian endometrioid carcinoma, 588-589
- Sertoli-Leydig cell tumors, ovarian, 597-599, 718-719
- Sex cord elements, in ovarian neoplasms, 588-589, 595-599
 fine-needle aspiration cytology of, 718-719
 immunohistochemical techniques in, 736-737
 in uterine neoplasms, 559-560
- Sexually transmitted diseases, diagnosis of, 665-684
 chlamydial infections, 665-671
 gonorrhea, 672-675
 herpes simplex virus infections, 675-678
 human papillomavirus infections, 680, 691-692
 syphilis, 678-680
 vaginitis/vaginosis, 680
- Sickle cell trait/disease, placental vascular lesions in, 620-621
- Small cell carcinoma, immunohistochemical techniques in, 738
 ovarian, 605-607
- Smooth muscle tumors, uterine, 562-571
- Southern blot hybridization, in human papillomavirus detection, 691-692
- Spiral artery lesions, 613-617
- Squamous cell carcinoma, cervical, 493-497, 729-730
 endometrial, 526
 vulvar, 465-471
 histology of, 473-476
 immunohistochemical techniques in, 728-729
 prognostic factors for, 471-473
 superficially invasive, 476-478
 treatment of, 763-764
- Squamous cell hyperplasia, vulvar, 457
- Squamous metaplasia, endometrial, 537-538, 540
- Stromal tumors, ovarian, sclerosing, 595-597
 uterine, 555-562, 732
- Struma ovarii, 603-604
- Surface syncytial change, endometrial, 540
- Syncytiotrophoblast, pathology of, in gestational trophoblastic disease, 633-634
- Syphilis, diagnosis of, 678-680
- Syringoma, vulvar, 463
- Teratoma, ovarian, 600-604, 719

- Thrombosis, fetal stem artery, 620-622
 intervillous, 618-619
- Transitional cell carcinoma, ovarian, 589-591
- Trophoblastic disease. See *Gestational trophoblastic disease*.
- Twin, in molar pregnancy, 638-640
- Uterine neoplasms, adenofibroma, 546-548
 adenomyoma, 548-549
 adenosarcoma, 549-551
 carcinosarcoma, 551-554
 cervical. See *Cervical lesions*.
 endometrial. See *Endometrial tumors*.
 immunohistochemical techniques in, 734
 leiomyoma, atypical, 569-571
 cellular, 568
 gonadotropin hormone-releasing hormone agonists and, 567-568
 mitotically active, 568-569
 leiomyomatosis, intravenous, 565-567
 leiomyosarcoma, 562-565
 mesenchymal, epithelial components with, 545-554, 733
 smooth muscle, 562-571
 stromal, 555-562, 732
 sex cord elements in, 559-560
 stromal, 555-562, 732
- Vaginitis/vaginositis, diagnosis of, 680
- Vascular lesions, of placenta. See under *Placenta*.
- Verrucous carcinoma, vulvar, 475-476, 729
- Villi, placental, in gestational trophoblastic disease, 633-638, 644-647, 649-650
- Villoglandular adenocarcinoma, endometrial, 520-521
- Vimentin, antibodies to, in gynecologic disease diagnosis, 732-733
- VIN (vulvar intraepithelial neoplasia), 457-461, 700-701, 728-729
- Vulvar lesions, 455-492
 aggressive angiomyxoma, 482-484
 benign neoplasia, 462-464
 Bowenoid papulosis, 461-462
 carcinoma, Bartholin's gland, 481
 basal cell, 478-479
 squamous cell, 465-471, 729, 763-764
 histology of, 473-476
 prognostic factors for, 471-473
 superficially invasive, 476-478
 verrucous, 729
 epithelial, non-neoplastic, 455-457
 evaluation of, 484-485
 immunohistochemical techniques in, 727-729
 intraepithelial neoplasia, 457-461
 human papillomavirus and, 700-701
 immunohistochemical techniques in, 728-729
 melanoma, 481-482, 727-728, 764-765
 Paget's disease, 479-481, 727-728
 treatment of, 763-765
- Vulvectomy, specimens from, evaluation of, 484-485
- Warts, genital, human papillomavirus and. See *Human papillomavirus*.
- Warty squamous cell carcinoma, vulvar, 473-475
- Yolk sac tumors, ovarian, 599-600, 721